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ObJtctiws. The rim of tbir study WBS to avs~ the abJUty oftbe 
cigoal-nversged olectrocardiognm (ECG) to predict the e&uy of 
orocainnmtde. 
Borkground The main role of tb signnlweraged ECG has 
been the identifkation of postiofarction palknls at risk of sodden 
destb. Prediction of the eiiicaq of botiirrhytbmk drugs ropre. 
Wn(s another potm3tiaJ clinkal application of this technique. 
Merhods.T4estud~exanincdtlnelP~a(~insml&on 
tha time domain a d speetrd temporot snSrysis of the signrl- 
averaged ECG in relation to the molts of prqvnmmed vmtric. 
ulsr stimulation studies In 31 patients with inducible sustained 
monomorpblc ventricutnr tacbycrwdin. 
Rrrrrlls. Pmwinnmide sipilicantly pmlooged tbs total tutd the 
initial QRS complex sod tow smplitudo signs1 dovstions (mun * 
SD135L30~s.161+46ms,p<0.0001;87t16va.98*20mr, 
p < O.OOOI, and 48 * 23 VS. 63 t 36 ms, p < 0.001, rqxctlvely) 
wbeveav the voot.mrsn.sqonre voltage of lhe toto1 QRS compkx 
and of the last 40 ms 01 the QRS complex ws signilicnntly reduced 
Late potentials, which are low amplitude signals Occurring at 
the end of the QRS complex, are believed to emanate from 
ueas of sIo\v conduction in myocardium from which reen- 
trant arrhythmias coo arise (I). They can be delected non- 
invasively from the body surface by the signal-averaged 
electrocardiogram (ECG) (2). To date, the main clinical role 
of late potentials is the identification of patients at risk of 
sustained ventricular tacbvcsrdia and sudden death u-7). 
Prediction of the eRica& of antiarrhythmic drugs r&c- 
sents another potential clinical application of the signal- 
temporal mapping d the signal.avenged KG were &dJsr 
before and after pmminamide sdndnistratiw. Proc&mdde we. 
vented tbe indtibility of wslsimd vtiri&r tacbycardi; or 
prdW&d the cyck kngth ofvrntriti tocbycardis by BIDO ms 
in 16 ptknts (52%) (vcspndcn). The fvactkmal pmtcagnlion of 
the LotslQRS duntt ~a$ sigoiinnU9 greMe’ in rqmnders 
(26 f 15%) than in nonmponders (10 * 10%) fp < O.Mlz) Md, 
wba uds probnylon was 215%, idatilied vqoiuem With I 
vositivity of 96%. b spftilkit9 oI 81% mid an ovenll predictive 
WWacY Of 90%. 
averaged ECG. There is growing evidence that floss IA. 
class IC and class 3 antiarrhythmic drugs significantly alter 
the signal-averaged ECG (S-12). but few reports have ex- 
amined the relation between drug-induced signal-averaged 
ECG changes and antianhythmic efficacy (10.11). 
To address this issue, we examined the effects of procain- 
amide. a potent and widely used antiarrhythmic drug. on 
signal-averaged ECG variables in relation to the results of 
programmed ventricular stimulation in a group of patients 
with sustained ventricular tachycardia. 
Methods 
The study group was prospectively selected from II0 
consecutive patients admitted to oov department after Octo- 
ber 1990 for serial drug testing because of a history of 
sustained ventricular tachycardia. in SE patients a sustained 
monomorphic ventricular tachycardia was induced. Of this 
group. 31 consecutive patients (25 men wbh a mean age of 
61 2 10 years) who underwent tertmg of procainamide 
among other autiarrhythmic drugs met the following entry 
criteria: 1) at least one spontaneous episode of sustained 
monomorphic ventricular tachycardia documented on a 12. 
lead ECG; 2) sustained monomorphic ventricular tachycar- 
dia inducible ut baseline programmed ventricular stimula- 
tion. and identical to the clinical arrhythmia; 3) no other 
sustained monomorphic ventricular txhycardia inducible at 
baseline stimulation; 4) no bundle branch block on the 
baseline ECG. The underlvinp. heart disease was orevious 
myocardial infarction in 2i oatieuts and idiopathic dilated 
cardiomyopathy in 7. Angiographically assessed ejection 
fraction was <30% in 8 patients (26%). 
All patients gave w&n consent. The pr010~0l of the 
study was approved by the local Ethics Committee. 
meats and computations were made automatically without 
manual intcruention. 
Time &,mobz anolysic. The time domain aoa(ysis of 
the signal-everaged ECG was performed at high pass 
filter settings of 25 and 40 Hz u&g u bidirectio&l four- 
pole Butterworth filter. After amplification. averaging 
and filtering. the signals were combined into a vector 
magnitude ‘/(I;’ + Y’ + 2’). and three conventiona! time 
do&n indexes were calculated: the duration of the tote! 
QRS complex. the duration of the low amplitude (al0 PV) 
~i~oo!s at the terminal o&on of the QRS comulex and the 
r&m”-pquare volt, of the last-40 ms bf the QRS 
complex. The result of the time domain signal-avenged 
ECG wus abnormal when at least two of three conventional 
variables were beyond the normal range: total QRS duration 
2120 ms; duration of low amplitude (~40 &V) signals 
Signai-Averaged Eiecr,oc::rrliogmphy 
Acquisition. The signal-averaged ECG was recorded 
from X, Y and 2 orthogonal leads using a recorder from 
Arrhythmia Research Technology (model I?W EPX). The 
end point of recording was a noise level of ~0.3 pV. 
To asses8 the short-tam reproducibility of the signal- 
wetaged ECG, two recordings were performed within 
15 min in 24 patients, usually I day before the electmphys- 
iologic study. Care wus taken to obtain similar noise levels at 
both recordings. A mean of 234 f 38 heartbeats (range I60 to 
280) were averaged to achieve u mean noise level of 0.25 e 
0.06 pv (range 0.2 to 0.4). 
The recordines beFore and after orocainamide infusion 
were obtained &tt the same elecirode position as the 
recordings of the repmducibility study. A mean of 240 2 41 
cardiac cycles (range 170 to 360) were avenged and the 
noise level rouged from 0.2 to 0.5 PV (mean 0.26 i 0.08). In 
no patient was the diffeerence in the noise level between the 
baseline recording and the recording during procainamide 
treab~ent >0.2 pV. A noise level 50.3 NV was achieved in 
50 recorditw 181%): in the remainina I2 recardines the noise 
level was 64 to 0.5 PV because ornoise prod&d by the 
equipment in the electrophysiology labot’utory. 
There were I I oral and 20 intravenous drug studies. lo 
oral drug studies the baseline signal-averaged ECG was 
recorded before and after 4.2 f I.3 days (ranse 3 to 7) of 
procainamide therapy (median dose 2,364 &day [rouge 
l.SMto4,OW1) within 2 h ofthe electrophysiologic study. in 
intravenous drug studies, the first signal-avenged ECG was 
recorded 5 min before the baseline stimulation, and the 
secund sianal-averwed ECG was obtained usinp. the same 
e&rod& between-5 and IO min after termination of the 
pro&amide infusion (750 to I .tYJO tug over IO min). and it 
was immediately (I to 3 min) followed by programmed 
ventricular stimulation. 
Analysis. The signal-averaged ECG recordings were 
stored and subsequently analyzed (FFT-Plus, version 3.10 ._ .-. 
240 ms. and root-mean-square voltage of the last 40 ms of 
the ORS comolex <25 uV at a 25.Hz filter settine (71 sod 
> Il4‘ms. >3bms and <iO *V. respectively. ut a &&filter 
setting (13). lo addition, two other signal-averaged ECG 
variables were calculated: the root-mean-sauare voltaxe of 
the total QRS complex and, as described bi Freedman and 
Steinbere 110). the initial QRS duntion. which was defined 
as the duration of the QRS complex preceding the low 
amplitude signal (i.e.. the duration of the QRS complex 
measured from the beginning of the complex to the pain: 
when vector-summed QRS forces last decreased to 
~40 pV). The analysis was perfonued at both filter settings 
because a significant difference may exist between the re- 
sults obtained at 25 and 40 Hz. The use of a 4C-Hz filter 
attenuates the voltage to a greater extent than does use of a 
25.Hz filter (14) and in some poslinfarciiou patients, espy 
cially during antiarrhythmic therapy, more than half of the 
total QRS duration can be ~40 @V. meeting the criteria for 
late potentials. The noise level is also a@xted by the filtering 
nnd is lower at 40 Hz (14). an effect that may cause 
discrepancies in the detection of the end of fit&d QRS 
duration by the noise-dependent algorithm when different 
filter settings ure used. 
Specrmirrmporal mapping. Spectral temporal mapping 
of the siaud-averaged ECG was performed with fast Fourier 
trausfor~ analy&by uualyzi~25 overlapping 80.ms seg- 
ments in 2.mr steps. The first segment began 20 ms before 
the end of the standard QRS complex. The mean adjustment 
was set at zero to eliminate any ST segment elevation or 
depression. The data were multip!ied by a Blackman-Harris 
window. Results of the spectral temponl mapping were 
expressed as B factor of normality. This factor was calcu- 
lated on the basis of a reference specttum, which was the 
average of the most distal 5 segments (i.e., spectra 21 to 25). 
Two mathematic Eomputations were made for the frequen- 
ties between 40 and I40 Hz. The tint vulue to be derived 
was the correlation coefficient of the frequency content of 
each of the 25 spectra as compared with the reference 
spectrum. The se&d derivative was based on the area 
_. . . . . . 
reference s~ec.trum. The abnormal result of the spectral 
temporal mapping was defined as the value of the normality 
factor <30% in any lead, according to Haberl et al. (15). 
Standard electroeardiwram. The standard ECG was 
recorded using the ART i200 EPX recorder immediately 
after the sianal-averaeed ECG was amuired. The standard 
QRS and GT mtervi durations weremeasured automati- 
cally by the computer algorithm. The corrected QT interval 
was calculated using Bazett’r for@a (16): corrected QT 
interval = QT intervali~~l. 
Programmed vcntrtcular stimuldtion. Baseline stireula- 
lion was performed after discontinuation of antiarrhythmic 
drugs for at least 5 half-lives before the study. Three 
quadripolar electrode catheters were introduced percutanc- 
ously to the femoral and subclavian veins and positioned 
under tluoroscopic guidance in the high right atrium, His 
bundle position and right ventricular apex. Intracardiac 
recordings were filtered at 30 to 500 Hz and displayed 
simultaneouslv with three surface ECG leads (I. aVF and 
V,) on an eight-channel Siemens-Elema Mingograf chart 
recorder. Programmed ventricular stimula’ion was per- 
formed using a Medtronic model 5326 nroerammahle stimu- 
lator with &angular pulses of 2.0-r& d&tion, delivered 
at twice diastolic threshold. A strict 12-step stimulation 
protocol consisted of introducing single- and double- 
extrastimuli at the tiht ventricular apex during sinus rhythm 
and after eight-beat;xtrnstimulus &) drive t&s at iaced 
cycle lengths of Mw), 500 and 400 ms. If a sustained arrhyth- 
mia was not inducible, the procedure was repeated using 
triple extrastimuli. According to the patient selection mite- 
tit+, the end point of the baseline stimulation was the induc- 
tion of clinical sustained ventricular tachvcardia. The end 
point of the study performed during proc&amide therapy 
was the induction of sustained ventricular tachycardia or 
ventricuiar fibrillation or comnletion of the orotocol. 
Definitions. Sustained :.en&ular tachycardia was de- 
fined as a tachycard a of ventricular origin, with a uniform 
QRS conligurat~on. .asting a30 E or causing hemodynamic 
collapse. Nonsustained ventricular tachycardia was defined 
as SIX or more beats of repetitive ventricular activity that 
was wll tolerated and lasted ~30 s. A sustained ventricular 
tachywrdb was defined 8s clinical when, in comparison with 
spontaneous ventricular tachycardia, the induced arrhyth. 
mia bud an identical or nearly identical QRS axis and 
configuration and a similar rate (a difference in a cycle length 
520 ms). The mode of termination of sustained &ric&r 
tachycardia was classified as I) spontaneous; 2) by introduc- 
tion of one premature ventricular beat; 3) by introduction of 
two ventricular premature beats: 4) by overdrive pacing: 
5) by cardioversion or defibrillation. The longest interval 
(defined to the warest 5 ms) at which a second extrdstimu- 
Ius, S,, introduced during sinus rhythm (5 patients)or pacing 
at a cycle length of MM ms (26 patients), failed to evoke a 
depolarization was termed the effective refractow period of 
the ventricle. The cycle length of ventricular tachycardia nd 
of the ventricular effective refractory period were measured 
by hand calipers at a paper speed of 100 mm/s. 
Effective treatment was defined as noninducihility of 
ventricular tachycardia or prolongation of the cycle length of 
ventricular tachycardia, which was hemodynamically stable, 
by blO0 ms during treatment with procainamide. Patients 
with effective treatment were termed responders. Patients 
with ineffective treatment were termed nonresponders. 
Stalistical methods. Continuous variables are presented 
as the mean value ? 1 SD. The paired I test was used to 
compare the signal-averaged ECG indexes before and during 
procainamide therapy. An unpaired f test was used to 
compare the numeric values of simml-averaeed ECG vti- 
able; between effectively and inetfectively &ted patients, 
and between patients with no inducible tachycardia and 
patients whose cycle length of ventricular tachycardia was 
prolonged by EIDO nts. A chi-squure test or Fisher exact test 
was used when appropriate to compare the results of the 
signal-averaged ECG before and during procainamide ther- 
apy. The effects of proeainamide on the inducihility (stage of 
pacing protocol) and the mode of termination of ventricular 
tachycardia were examined “sing the Wilcoxon signed-rank 
test. 
The absolute change in the time domain variables caused 
by procalnamide wns calculated as the dtirence between 
two sigoalaveraged ECG observations. The fractional (per- 
cent) change was calculated BS the absolute ditTerence be- 
twsen two measurements divided by the value of the tirst 
measurement. The baseline reproducibility of the signal- 
averaged ECG, and the correlations between the signal- 
averaged ECG variables and the cycle length of ventricular 
tachycardia and the ventricular effective refractory period, 
were tested with the “se of Pearson’s correlation coefficient. 
In all statistical tests. a two-tailed I) value < 0.05 was 
required for statistical significance. S&itivity was defined 
as the number of true positive results divided by the number 
of true wsitive plus false negative results. Snecificitv was 
defined & the nttmber oftrne negative results &vided iy the 
number of true negative plus false positive results. The 
overall predictive accuracy was defined as the number of 
true positive plus true negative results divided by the total 
study group. The sensitivity and specificity of identification 
of etTectively treated patients were computed for the frnc- 
tional changes of each signal-averaged ECG variable and for 
all possible dichotomizing values. 
When testing for st&stical associations of the signal- 
wewed ECG results with drue inhibition of ventricular 
tachy&rdia, the Bonferroni correction (multiply the probe 
by the number of tests) was applied to the IO analyzed p 
values (see Table 3). 
Results 
B&!&w reproducibility of the sign&averaged ECG. The 
reproducibiliiy of the lime domain signal-averaged ECG 
variables at ” 25.Hz filter setting was high: the Pearson’s 
C 
FIgwe 1. Wtienl 1. Signal-averaged elecmcardiographic IECG) 
newdings from a padent with an anterolaterd infantton. The 
baseline time domain signal-averaged ECG was normal (A) and the 
results of the spectmt emporal mpppiag were within normal imits 
(for example. rbe normality factor in lead Z was 92%) (I). Procain- 
amide prevented iaducibility of sustained ventricular tarhycardia. 
After drug administration. all conventional time domsn signal- 
averaged ECG indexes became abnormal (0 Tk pmlongation of 
the total QRS duration (the fractional irxrease was 25%) was cawed 
by pmlongation of the low amplitude signal duration whereas the 
duation of the inilial QRS eemplex remained unchanged. The 
~sults of the spwtml ternpant mapping were similar to those of the 
baseline recording (the normality factor in lead 2 war 1046) (D). 
LAS = low amplitude signal duration: RMS40 = the root-mean- 
sqtere voltage of the last 40 ms of the QRS complex: RMSQRS = 
the root-mean-square voltage of the total QRS complex. 
correlation coefficient was 0.99 for the total QRS duration, 
0.9g for the low amplitude signal duration. 0.99 for the initial 
QRS duatioo. 0.94 for the mot-mean-square voltage of the 
last 40 ms of the QRS complex and tl.99 for the root-mean- 
square voltage of the total QRS complex. The qualitative 
results of the time domain siyalwemged ECG (normal or 
abnormal) were consistent. The use ofthe &Hz filter setting 
did not change the results. 
The reproducibility of the spectral temporal mapping was 
worse than that of the Lne domain analysis. The Pearson’s 
correlatnn coetiicients for the normality factors computed 
for the X. Y. 2 leads, and the comtwsite laxis were 0.79, 
0.51.0.72 and 0.4& respectively. In &ur patients the results 
of spectral temporal mapping were inconsistent. 
E&D of ptwrdoamW en the si@ml.averagcd ECG. The 
examples of the elfects of procainamide on the signal- 
aveneed ECG are eresented in Fiawes I and 2. At the 
baselik study (before procainamidekfusion). an abnormal 
sienal-aveneed ECG at a U-Hz filter setline was diaenosed 
b-16 trials ?52%), and at 40 Hz in 23 r&dings (74%). 
During procainamide therapy. 24 recordings (77%) at 25 Hz 
and 27 recordings (87%) at 40 Hz were classitied a.s abnor- 
mal. Pmcainamide significantly changed all time doaain 
variables. The overall results are presented in Figure 3, and 
the fmctional changes in the signal-averaged ECG indexes 
with corresponding absolute changes in the cycle length of 
ventricular rachycxdia in individual patients are shown in 
Table I. The total and initial QRS complex and low ampli- 
tude signal durations were prolonged (13.5 + 30 vs. I61 i- 
46 ms, p = O.wOI; 87 f I6 ms vs. 98 2 20 ms, p = O.OCQl, 
and 48 ? 23 ms vs. 63 5 36 ms, p = 0.001, respectively) 
whereas the root-mean-square voltage of the wtal QRS 
complex and of the last 40 ms of the QRS complex was 
reduced I I2 +_ 36 WV vs. 87 r 36 WV, p = 0.0001) and (21 f
I9 WV vs. 13 * 12 PV, p = 0.002. The most consistent 
changes occurred in the total QRS duration, which was 
prolonged in all but one recording, and in the root-mean- 
square voltage of the total QRS complex, which was reduced 
Ftgure 3. Effects of procainamide on the mean total QRS, low 
amplitude signal and initial QRS durations and on the root-meam 
square voltage of the last40 ms and of the total QRS complex. Blpek 
bara = measurements before procainnmide; “bite bnn = measure- 
ments during procainamide therapy. iQRS = initial QRS duration; 
TQRS = total QRS duration; other abbreviations a in Figure 1. 
Figure 2. Patient 3. The signalweraged electrocardiographic 
IECG) recordings from a patient with an anterior infarction. The 
baseline time domain signalweraged ECG was abnormal (A), 
whereas results of the spectral temporal mapping were within 
normal imits (for example. the normality factor in lead X was 91%) 
(8). Pro&amide prevented inducibilily of sustained ventricular 
tachycxdia. On the time domain signal-averaged EC0 (0, the total 
QRS duration WE prolonged by the drug by 22 mu (the lractional 
increase of 2U%). The initial QRS prolongation WBF gree.tcr than the 
tow ampktude signat pmbmgation (17 “I. 6 ms. or 27% YS. 12%). 
The reruleofspctraltempnral mappingwere similar to those ofthe 
baseline recording (the normality factor in lead Z was I@l%) (0). 
Abbreviations as in Figure 1. 
in 7.8 trials (9G%). The low amplitude signal duration was 
prolonaed in 23 trials 174%). the initial ORS duration was 
&x&d in 26 (84%). whereas the rc&ttean-square volt- 
age of the last 40 mr of the QRS complex was reduced in 26 
recordings (84%) (all results at 25 Hz). The absolute prolon- 
gation of the initial QRS complex and the low amplitude 
signal durations were similar (II -C IO ms vs. IS f 22 ms at 
25Hz,p=NSand9il0msvs.l0~18msat40Hz,p= 
NS). The absolute increment in the low amplitude signal 
duration constituted 57% (25 Hz) or 52% (40 Hz) of the 
absolute increment in the total QRS duration. The ftactional 
increase in the low amplitude duration exceeded the 
frxtional increase in the initiil QRS dwation (32 + 45% vs. 
13 f 11% at 35 Hi. p = 0.037 and 20 r 28% vs. 12 + 1 I% at 
40 Hz. p = NS). 
No significant dihrence was noted between the hat- 
tional changes in the time domain signal-averaged KG 
variables ir, patients with late potentials and those m patients 
with a normal signal-averaged KG. Among 24 postinfarc- 
lion patients, the initial QRS duration was wore prolonged 
in those with an anterior versus an inferior site of infarction 
(14 t_ I2 vs. 6 f; 6 ms, p = 0.05 or 18 + 13% vs. 8 + 7%. 
p = 0.016). 
The eLcts of the d,ug on the results of spectral temporal 
mapping of the sign&averaged ECG were not significant: 
the values of the normality factor were similar before and 
duringpmcainamide therapy in all leads (57 + 32% us. 56 i 
32% in lead X. 43 + 30% vs. 43 t 32% in lead Y. 52 2 33% 
vs. 51 ? 30% in lead Z and 44 = 31% vs. 45 z 29% in ihs 
composite lead, p = NS for all differences). The abnormal 
spectral temporal mapping was diagnosed in 20 patients 
(65%) before pmcainamide therapy and m 19 (61%x) after 
pro&amide therapy (p = NS). 
On the standard ECG. procainamide signifitnntly pm- 
longed the duration of both the QRS complex (98 2 I3 vs. 
109 2 I8 ms, p = O.Oa301) and the corrected QT interval 
(448 + 36 vs. 472 -L 34 ms. p = O.W2). 
The effects of oral versus intravcnou prwainamide on 
the time domain signal-averaged ECG variables were simi- 
lar: the fractional changes in the signal-averaged ECG in- 
dexes in both groups are presented in Table 1. 
RUeas d pmeaintunide on lbe rwl$ of pmgmmmed 
venbicu*r stimulation. Procakwnide prevented inducibility 
of sustained venuicular tachycardia in six drug trials W%e): 
in five patients xw arrhythmia was inducible and in one 
patient only short runs (up to eight QRS complexes) of 
tacbycardia could he induced. In the remaining 25 dials 
sustained ventricular tachycardia remained inducible but its 
cycle length WE significantly prolonged (308 + 62 vs. 384 2 
91 ms, p < 0.001). Individual results are presented in Table 
I. In live patients the axis of the QRS complex during 
ventricular tacbvcardia was different from that i:l the base 
line study but tie configuration of the QRS complex during 
tacbycardia was unchanged (the same bundle branch block- 
like pattern). No patient had spontaneous occurrence of 
arrhythmia or acceleration of a rate of induced ventricular 
tachycardia after procainamide administration. In summary, 
an effective treatment was achieved in 16 drug trials (52%): 
in 6 trials (5 intravenous and I oral) sustained ventricular 
tachycardia became noninducible, and in 10 trials (5 intra- 
v&us and 5 oral) the cycle length of suslained ventricular 
tachycardia was prolonged by rlOO ms. 
Roainamide signilicantly increased the ventricular ef- 
fective refractory period (267 f 34 vs. 292 + 37 ms. p = 
o.oow. 
Of25 studies in which ventricular tachycardia was still 
inducible during procainamide tkczzpy, arrhythmia was in- 
duced in II (44%) at a lower stage of the protocol, at the 
same stage in 8 012%) and at a higher stage in 6 (24%). 
Overall. procainamide did not e&t an induction of v;:tti;- 
ular tachycardi;?: the mian diiercnce in the stage of the 
pacmg protoco! zt ??+ict tachycardia was inducible was 0.4 
(5.6 stage at bareliw Y~FIS 5.2 stage on procainamide, p = 
NS!. The mode of termination of ventricular tachycardia 
during pmcainamide therapy was less aggressive than the 
terminauon of the baseline arrhythmia in 9 studies !36%L 
unchanged in I? (48%) and more aggressive in 4 studies 
(l6%_). Overall. mocainamide facilitated termination of ven- 
tricular tachycardia: the mean difference in the stage at 
which tachycardia was terminated was 0.9 (4.4 stage at 
baseline \s. 3 5 stage during therapy, p < 0.03). 
Correlation, behveen sigwlsvemged ECG arid &etmpkye 
iologic shtdy findings. At baseline stimu(aticm. a significant 
correlation was found between the cycle length of ventricu- 
lar tnchycardia and the total QRS complex at 25 Hz (Table 
?I. .ARsr procainamide administration, acorrelation between 
the signal.averaged ECG variables and the cvcle length of 
tachycardra was stronger. Only the voltage of the total QRS 
comp’c , did not correlate witk the cycle length of tacbycar- 
dia. The magnitude of the total QRS duration correlated 
better than did other variables with the cvclc I? *gth of . _ 
ventricular tachycardia. 
No correlation was found between the ventricular effec- 
tive refractory period and the signal-averaged ECG in either 
the baseline or the procainamide studies. 
ReMon between pmcaiasmtde-iiueed sign&averaged 
EGG changes sttd twulB of p ventricular stimu- 
lation. The percent changes of the signal-averaged ECG 
variables cawed by pwcainamide in effectively treated 
patients (responders) ve~su? those in patients whose treat- 
ment was unsuccessful (nonresponders) are compared in 
Table 3. The variable that showed the most con&en1 
sign&ant difference between groups was the fractional 
incrense in the total QRS duration, which was greater in 
responders than in nonresponders (26 ? 15% vs. IO L 10% 
at iS Hz, p = O.MI2 and 50 + % YE. 8 * 10% at 40 Hz. 
D = 0.001~ Tb individual values of the fractional changes 
in the total QRS duration at both filter settings we presented 
in Figure 4. The total QRS duration wets proionged by 
k 15% at 25 Hz (vertical line in Fig. 4) in IS responders (94%) 
(6 whose arrhythmia became noninducible and 9 whose 
ventricular tacbycardia cycle length was prolonged by 
rlOO msl, but lhis degree of prolongation occurred in only 
2 nonresponders (13%) (p = O.WI), resulting in a sensitivity 
of 94%.‘a specificity if &7% and an overall predictive 
accuracv of 90% for this variable. The same level of sensi- 
tivity bit lower levels of specificity (67%) and overall 
predictive accuracy (Sl%) were achieved for t?actional pro- 
Ioncation of the total ORS comolex hv 813% at 40 Hz 
(ho&x&d line in Fig. 2). The ;ensiti;ity and specificity 
curves also showed that for various dichotomy points the 
fractional prolongation of the total QRS duration at 25 Hz 
provided higher sensitivity without a corresponding signiti- 
cant decrease in specificity than did the fractional change in 
thz total QRS duration analyzed at a 40.Hz high pass filter In the responders, procainamide-induced signal-averaged 
se:ting (Fig. 5). ECG alterations were similar in 6 patients whose ventricular 
On the standard ECC. the fractional prolongation of the tachycardia became noninducible and in IO patients whose 
QRS complex was significantly greater in responders than in cycle length of ventricular tachycardia was prolonged by 
nonresponders :15 2 II% vs. 7 * %, p = 0.029) whereas ElDO ms (Tsble 4). 
corrected QT prolongation was similar in these groups (4 c The absobtc and fractianat prolongation of the ventricu- 
IO% YB. 7 2 7%. p = NS). Ix etkctive refractory period was signiticantly greater in 
responders than in nonresponders (37 + I5 vs. I3 ? I8 ms. 
pi 0.001 and 14 r 7% vs. 5 k 7%. p < 0.092. respectively). 
The changes in refractoriness in patients whose tachycardia 
became noninducible and in patients in whom vam’icular 
tachycardia was still inducible but with the cycle length 
prolonged by al00 ms were similar (37 t 12 vs. 37 + iS ms 
and 14 f 7% vs. 14 f 7%. respectively). 
Tabk 3. Comparison of the Pmcainamide-Induced Fractional 
Changes in the Signal-Averaged KG Variables m Responders 
Versus Nonresw”den 
Diicwion 
Fin&w of Ihn shdv. Our maior findings are that I) mu. 
these variables predict proainamide e&y, defined <no”- 
induabddy of sustained arrhythmia or pmkmgatiw of the 
cycle length of ventricuiar tachycadia by ~100 ms. 
Although initial repons (17) suggested a lack of influence 
of antiarrhythmic drugs on the signal-averaped ECG. more 
recent reports have shown that class IA drugs (procain- 
amide. quinidine, imipramine) (8.10). c!w IC drugs (pro- 
pafenone. flecainide) (IO-13, and amiodarone (9) signifi- 
cantly change the signal-averaged ECG. Freedman and 
Steinberg (10) have also suggested that class I drugs sclcc- 
tivcly prolong late potentials whereas other variables arc less 
affected. However, Lombardi et al. (I 1) have postulated that 
class IC drug-induced signal-averaged ECG changer reflect 
an inhomogeneous lowing of intramyocardial impulse prop- 
agation. 
In the present study we also observed significant 
procainamide-induced alterations in all time domain vari- 
gbles. The root-mean-square voltage of the total and of the 
final 40 ms of the QRS complex were reduced. whereas the 
total QRS duration wus prolonged. Both components of 
the total ORS comolex. the initial OR.5 and the low ampii- 
tude rigna~duratio&, were a!so signkantly prolonged, &d 
the absolute increase of these variables was similar. The 
fractional increase in the low amplitude sianal duration 
tended to be greater than an incr&sc in thi initial QRS 
duration but it reached borderline significance only al a 
2S.I-k tiller setting. This observation may suggest some 
preferential effects of procainamide on late potentials as 
reported by Freedman and Steinberg (10). However, in our 
study the total and the initial QRS durations were prolonged 
more consistently than was the low amptitude signal dura- 
tion. and the absolute increment in the Low amplitude signal 
%Cabte 4. Fractional Changes in Time Domain Signal-Averaged 
Electrocardiographic Indexes (at 25 Hz) in Patients in Whom 
Prncainarnidc Prevented lndueibility of Ventricular Tachycardia 
or Prolonged Its Cycle Length by rlM) ms 
sitre 5. Plats of sensitivity and specificity curves of fractional 
changes IA%) of the total QRS durations that were aWLed using 
25 Hz (t&t) and I Hz (right) high part tilterr to identify pauents in 
wham procainsmide prevented inducibility of ventricular tachyear- 
dia or prolonged its cycle length by slOIl ms. Horizontal ax6 
correspond to dichotomy points, and nrtkti M show valuer for 
sensitivity and rpecikiry. Vahws for sensitivity (tkick tine) and 
weciticity lin line) are shown Or each possible dichotomy point. 
duration constituted 52% to 5’7% ofthc absolute increment in 
the total QRS duration compared with the increment of 73% 
reported by Freedman and Steinberg (IO). The discrepancies 
between their findings and our results may be explained by 
di5crences in study groups (they also studied patients with 
ventricular fibrillation and syncope), the use of other than 
procainamide class I antiarrhythmic drugs in their study and 
possible differences in the baseline frequency of late paten- 
tials in the two studies. 
Procainamide significantly prolonged the duration of the 
QRS complex on the standard ECG but the fractional 
increase in the QRS duration detected by the signal-averaged 
ECG was greater than that detected by the standard ECG. 
Procainamide did not sknificantlv alter the results of the 
spectral temporal mappingif the s&al-averaged ECG. The 
values of normality factor as well as visual inspection of 
spectral temporal maps did not reveal any significant or 
specific changes produced by the drug. These findings, 
although of limited value because of the poor reproducibility 
of the spectral temporal mapping in the present study and a 
previous study from this labomtory (IS), further suggest hat 
procainamide-induced changes in the time domain signal- 
averaged ECG may be nonspecific rather than selective 
molonaation of late ootentials. This conceut is in nccord 
with the findings of another study from this kwatory (12). 
in which Aecainide-induced alterations in time domain vari- 
ables were identical in oatients with ventricular tachycardia 
and late potentials ani in patients with supmvcnkicul~ 
tachycardia, no structural heart disease and a normal signal- 
averaged ECG. 
The duration of the signal-averaged QRS complex con-c- 
lated with the cycle length of ventricular tachycardia but no: 
wth the ventricular effective refmaory prrlod a, tht base- 
line study. Similar findings have been reported by Borbola et 
al. (19). During procsinamide therapy. more signal-averaged 
ECG variables correlated with the cycle length of ventricular 
tachycardia, and the correlation was stronger than at the 
baseline studv. This findinn mav he exolained in uan bv the _, 
observations of De Lattgen et al. (20). who have shown that 
procainamide caused greater prolongation of electmgrams 
ending late in the QRS complex than of those that end 
earlier, resulting m a greater prolongation of the terminal 
portion of the QRS complex on the surface stgnal-avenged 
ECG. However, Schmitt et al. (?I! were anable to detect a 
differential effect of antixrhythmic drugs on normal and 
abnormal electragrams in humans. In thcpresent srudy the 
ORS duration correlated better with the cvcle leneth of 
&ricular tschycardia than did the low amplitude s~gnai 
duration. a finding that agrees with the observation (22) that 
local electragram duration does not neccnsarily correlate 
with the cycle length of tachycardia. 
Cmttparison with previous wwk. The relation between 
drug-induced signal-averaged ECG changes and antmrrhyth- 
mic efficacy has been examined in only IWO previous studier. 
In the first of these. Freedmar. and Steinberg (iOl shuwed 
that prolongation of the low amplitude signal duration by 
class I antiarrhythmic drugs correlated wth the increase in 
the cycle length of ventricular tachycardia. The number of 
patients in whom antiarrhythmic drugs prevented inducibil- 
ity of ventticulat tachycardia was too small to make any 
conclusions. In the second study Lombardi et al. (II) 
showed that propafettone- and Recainidc-induced changes in 
the signal-averaged ECG were not related to antiarrhythmtc 
efficacy assessed by Holler monitoring. 
Procainamide is effective and widely used as first-line 
therapy in many patients with ventricular tachycardia. There 
is evidence (23) that noninducibility or prolongation of the 
cycle length of ventricular tachycardia by nlDO ms during 
pro&amide therapy is associated with a favorable progno- 
sis. In the present study the best signal-averaged ECG 
variable for identiiicatian of such patients was the increase in 
the total QRS duntion, which represents procainamide- 
induced prolongation of conduction 124). Soae investigators 
have also ducumented that these effects are related to drug 
efficacy. Marchlinski et al. (25) showed that the degree of 
increase in the QRS duration. measured at B paced cycte 
length similar to that of ventricular tachycardia. correlated 
with the degree of slowing of the cycle length of tachycxdia. 
In other studies (24-27). the degree of prolongation of 
ventricular refractoriness identified responders more xcu- 
rately than did the degree of prolongation of conduction. In 
the present study responders had greater prolongation of the 
ventricular effective refractory period than did nonre- 
spenders, a finding that is in agreement with these studies. 
However, it is unclear why the prolongzation of conduction 
and refractoriness was similar in two subgroups of respond- 
ers (in patients whose tachycardia was rendered noninduc- 
ible and in patient- with indxible but slow and stable 
ventncular tachycardia). Presumab!y. complete wppressian 
of inducible ventricular tachycardia requires development of 
bidirectional block, whsch may depend not only on the 
magnitude of the drug-induced changes but also on the 
clcctrophysiulugic properties of the substrate in individual 
patients. 
Technical considerations. Detailed analysis of the effects 
of antwrhytbmic drugs on late potentials detected by the 
Ggnal-averaged ECG may be difficult. There is growing 
widence (28) that in many patients, especially those with an 
anterior sate of myocardial infarction, late potentials are 
hidden within the QRS complex and cannot be detected on 
the lure domain s&l-ave&ed ECC. Our finding thar the 
initial QRS duration was prolonged by procainamide to a 
greater extent in patients with anterior than in those with 
inferior infarction agrees with this concept. Currently. only 
spectral turbulence analysis of the signal-averaged ECG 
at!emp?s to detect late potentials located inside the QRS 
cumplex 129). 
The assumption that the low ;Implitude signal portion 
arises in each case frum slowly conducting tissue is undoubt- 
edly an oversimplification. Even if it holds flue in a signifi- 
cant .xoportion of postinfarction patients, it is still difficult to 
prove that the low amplitude signals at the end of the QRS 
complex indeed represent the slowly conducting area from 
where the clinical or inducible ventricular tachycardia orig- 
inates. 
The cutoK voltage of 40 PV used for definition for iate 
potentials was established in patients while they were re- 
ceiving no nntiarrhythmic treatment. Because these drugs 
significantly reduce the voltage of the total QRS complex (in 
our study by 2%). P large portion of the QRS complex may 
meet this criterion not because of true prolongation of late 
potentials but because of a nonspecific reduction in the total 
QRS voltage. Therefore, total QRS d!!rztion and other 
signal-averaged ECG variables that do not depend on QRS 
voltage may be more accurate than other variables for 
assessing the rKects of amiarrhythmic drugs on the signal- 
avenged ECG. 
Some studies have show !ba! the total QRS duration is 
more reproducible than the terminal QRS measurements, 
which are highly sensitive to the signal to noise ratio 
(18.30.31). Steinberg et al. (32) recently reported that the 
total QRS duration, but not the low amplitude signals or 
temxinal QRS voltage, contributed independently to the 
prognostic value of the signal-avenged ECG in postinfarc- 
lion patients. Because relatively small changes in the QRS 
oKset are likely to reduce the accuracy of terminal QRS 
measurements. the total QRS duration may be a less arbi- 
trary measurement hat includes the late wentials and the 
standard QRS complex. These tindings~may also partly 
explain the results of the present study. 
Limitntions of the sludy. Patients who were treated with 
intravenous procainamide underwenl electrical stimulation 
15 min after termination of the drug infusion rather than 
the prolonged infusion during stimulation that some in- 
vestigators (33) have advocated. Frocainamide was admin- 
istered orally in I I trials and intravenously in the nxnaining 
20 trials. However, the effects of oral and intravenous 
procainamide on the signal-averaged ECG indexes were 
similar. Although we did not routinely measure procain- 
amide and N-acetylprocainamide plasma levels, the doses 
used in the present study are comparable to procainamide 
doses &ted in other studies (23-25). Furthermore, even if 
pharmacokinetic differences influenced the results of pro- 
grammed stimulation in individual cases, they are unlikely to 
have altered the relation between the drug-induced s&d- 
averaged ECG changes and antirahythmic efficacy. 
In the present study no patient manifested prowrhythmic 
effects of procainamide, defined as ac&ratinn of elirkd 
arrhythmia, or induction of new sustained arrhythmia. Thus, 
we cannot exclude the possibility that some signal-averaged 
ECG changes, such as an increase in total QRS or low 
amplitude signal durations greater than those reported in the 
present study, may identify proarrhythmic effects of pro- 
cainamide. We also cannot e&de the possibility of accel- 
eration of a rate of ventricular tachycardia tith wrrespond- 
ing shortening of total QRS and low amplitude signal 
duration. 
Future directions. This study concentrated on the rela- 
tion between procainamide-induced signal-averaged ECG 
changes and resuib% of ventricular stimulation studies. Fur- 
thcr prospective stlldies are required to establish the role of 
signal-averaged ECG in predicting the long-term outwme in 
patients treated wi:h procainamide. 

